N
IRWD icon

Natixis’s Ironwood Pharmaceuticals IRWD Stock Holding History

Natixis’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$8 – 1120
2024
Q3 		$8 Hold
2
– – ﹤0.01% 945
2024
Q2 		$13 Hold
2
– – ﹤0.01% 974
2024
Q1 		$17 Hold
2
– – ﹤0.01% 993
2023
Q4 		$23 Hold
2
– – ﹤0.01% 1017
2023
Q3 		$19 Hold
2
– – ﹤0.01% 960
2023
Q2 		$21 Sell
2
-223,648
-100% -$2.4M ﹤0.01% 1001
2023
Q1 		$2.35M Buy
223,650
+221,269
+9,293% +$2.48M 0.02% 391
2022
Q4 		$29.5K Buy
+2,381
New +$27K ﹤0.01% 960
2015
Q2 		– Sell
-14,328
Closed -$192K – 404
2015
Q1 		$192K Buy
+14,328
New +$188K ﹤0.01% 407

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Natixis's IRWD Position: Q4 2024 in Review

Natixis sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2024, closing a stake of 2 shares — an estimated $8 sold.

Natixis first reported a position in IRWD in Q1 2015 and held it in 9 quarters. The position peaked at $2.35M in Q1 2023. 223 funds tracked by Wall St. Rank hold IRWD as of Q4 2024.

  • Natixis reported no remaining Ironwood Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Natixis sold 2 Ironwood Pharmaceuticals shares in Q4 2024, an estimated $8.
  • Natixis first reported a position in Ironwood Pharmaceuticals in Q1 2015 and held it in 9 quarters.
  • Natixis's Ironwood Pharmaceuticals position peaked at $2.35M in Q1 2023.
  • 223 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2024.

Based on Natixis's 13F filing for Q4 2024, filed 13 Feb 2025.